How Highly Active Antiretroviral Therapy Treats HIV

Highly active antiretroviral therapy, commonly known as HAART, is a combination drug strategy that transformed HIV from a near-certain death sentence into a manageable chronic condition. Patients who start treatment early can now expect a near-normal lifespan.¹ The approach works by combining drugs from different classes so they attack HIV at multiple points in its life cycle simultaneously, making it far harder for the virus to develop resistance. But while HAART suppresses the virus to undetectable levels, it does not eliminate it entirely, and the therapy comes with side effects, adherence challenges, and a complex relationship with the body that continues to surprise researchers.

From Death Sentence to Manageable Condition

Before HAART arrived in the mid-1990s, an HIV diagnosis carried a grim timeline. AIDS-related death rates climbed steadily through the early part of that decade, peaking around 1995.² Once combination therapy became widely available, those death rates fell sharply. In HIV-infected children, mortality dropped from about 7.2 deaths per 100 person-years in 1994 to 0.8 per 100 person-years by 2000. Children who started HAART had roughly half the mortality risk of those who did not. The proportion of deaths caused by opportunistic infections also fell, from about 37% in the mid-1990s to around 24% after 2000.³

The speed of this reversal was remarkable. Earlier attempts at treating HIV used single drugs or two-drug combinations, but the virus mutated around them quickly. The insight behind HAART was that hitting the virus from multiple angles at once made escape mutations far less likely. That principle still underpins modern HIV treatment, even though the specific drugs and combinations have changed considerably since the late 1990s.

How Combination Therapy Drives Viral Suppression and Immune Recovery

When someone starts HAART, the viral load in their blood typically drops within the first month and stays low as long as they keep taking the drugs.⁴ Meanwhile, CD4 T-cells, the immune cells HIV destroys, start climbing. In one study, the biggest jump in CD4 count happened around the third month and then leveled off. With newer drugs like dolutegravir-based regimens, viral loads can drop from hundreds of thousands of copies per milliliter at baseline to essentially zero within six months, while CD4 counts rise steadily over the same period.⁵

The pace of immune recovery matters. Research has shown that the speed at which the virus decays in the first year of treatment predicts how quickly CD4 cells bounce back during those early months. But the cumulative amount of virus the body was exposed to before suppression was achieved becomes more relevant to longer-term CD4 gains after the first two years.⁶ In plain terms, the sooner you start treatment and the faster the drugs knock the virus down, the better your immune system recovers, both short and long term.

Treatment as Prevention

One of the most consequential discoveries about HAART is that it prevents transmission. The PARTNER2 study followed nearly 800 gay couples in which one partner had HIV and the other did not. Over roughly 1,600 couple-years of follow-up, including more than 76,000 reports of condomless sex, there were zero cases of HIV transmission when the positive partner’s viral load was suppressed by treatment.⁷ This finding gave scientific backing to the slogan “Undetectable = Untransmittable” (U=U) and reshaped public health strategy worldwide.

The concept of “treatment as prevention” has pushed many health systems toward offering antiretroviral therapy to everyone diagnosed with HIV, regardless of how advanced the disease is, rather than waiting until immune counts fall below a threshold.⁸ The logic is straightforward: every person on effective treatment who achieves viral suppression is a person who will not pass the virus to a partner, a child during pregnancy, or anyone else.

Why HAART Cannot Cure HIV

For all its power, HAART has one critical limitation: it does not eliminate HIV from the body. The virus hides inside resting memory CD4 T-cells, embedding its genetic material into the cell’s own DNA. These cells can remain dormant for years, invisible to both the immune system and antiretroviral drugs.⁹ The moment treatment is stopped, the virus reactivates from these reservoirs and viral load rebounds, usually within weeks.

This latent reservoir is the central obstacle to a cure. It is established very early in infection and remains stable over decades of otherwise successful treatment.¹⁰ Researchers are exploring strategies to flush the virus out of hiding (“shock and kill” approaches) or to permanently silence it, ideally combined with aggressive antiretroviral therapy.¹¹ So far, only a handful of individuals have been functionally cured, and all through bone marrow transplants from donors with a rare genetic mutation, a procedure far too risky and impractical for widespread use. For the foreseeable future, HAART remains a lifelong commitment.

Drug Resistance and the Adherence Relationship

HIV mutates rapidly, and if drug levels in the blood drop low enough to let the virus replicate but remain high enough to exert some evolutionary pressure, resistant strains can emerge. The relationship between adherence (how consistently someone takes their pills) and resistance is not as simple as “miss doses, get resistance.” It depends heavily on which drugs are in the regimen.

Different drug classes have what researchers call different genetic barriers to resistance. Some drugs, like the older first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine, can be defeated by a single mutation. Others, like the boosted protease inhibitors darunavir and tipranavir, require many mutations before the virus can replicate effectively in their presence.¹² With low-barrier drugs, even modest lapses in adherence can select for resistant virus, because the mutations that confer resistance do not cripple the virus much.¹³ With high-barrier drugs, resistance requires the virus to accumulate multiple mutations over time, which is harder to do if the person is taking their medication most of the time.¹⁴

This is one reason modern regimens increasingly favor high-barrier drugs like dolutegravir and bictegravir (second-generation integrase inhibitors). They are more forgiving of imperfect adherence, and they tend to be combined into single-tablet regimens that simplify dosing to one pill per day.¹⁵

Side Effects That Shape Drug Choice

HAART is far better tolerated today than it was in the early years, but it is not side-effect-free. The choice between specific drugs often comes down to their safety profiles across several dimensions.

Kidney and Bone Health

Tenofovir disoproxil fumarate (TDF), one of the most widely used backbone drugs in HIV treatment, has long been associated with kidney stress and bone mineral density loss. Its newer formulation, tenofovir alafenamide (TAF), was developed specifically to address these problems. Head-to-head comparisons show that TAF preserves kidney function and bone density significantly better than TDF. After 12 months, people on TAF had measurably better kidney filtration rates and gained bone density where people on TDF lost it.¹⁶ Improvements in kidney and bone markers continued through 96 weeks in people who switched from TDF to TAF.¹⁷ This bone safety advantage also holds when TAF is used for HIV prevention (PrEP): people under 35 on TAF actually gained bone density, while those on TDF lost it.¹⁸

Weight Gain

Integrase inhibitor-based regimens, particularly those containing dolutegravir, are associated with more weight gain than older drug classes.¹⁹ In one study, people who switched to an integrase inhibitor gained an average of about 2.5 kg over two years, compared with roughly 1.1 kg in a control group staying on other regimens.²⁰ Researchers are now investigating whether differences in gut bacteria might help explain why some people gain more weight than others on these drugs, with early findings identifying specific microbial species that correlate positively or negatively with weight change.²¹ The weight gain is real but has to be weighed against the fact that integrase inhibitors are among the most effective and best-tolerated antiretrovirals available.

Cardiovascular Risk

HIV-positive adults on antiretroviral therapy carry a higher lifetime cardiovascular risk than HIV-negative controls. In one Tanzanian cohort, about 35% of people on ART were classified as high lifetime cardiovascular risk, compared with 17% of HIV-negative controls. The prevalence of metabolic syndrome was also roughly three times higher among those on treatment.²² Whether this is driven primarily by the drugs, by chronic inflammation from the virus itself, or by both remains an active area of study. In practice, it means that heart health monitoring is an important part of long-term HIV care.

Long-Acting Injectables

The newest shift in HIV treatment is the move from daily pills to long-acting injectable formulations. Cabotegravir plus rilpivirine, given as an injection every one or two months, was the first such regimen approved for maintenance therapy. In clinical trials, about 93% of people receiving the injections had undetectable viral loads at 48 weeks, which met the statistical bar for being as effective as daily oral therapy.²³

The appeal goes beyond convenience. Long-acting injections avoid “pill fatigue,” reduce drug interactions with food and other medications, and offer privacy. Someone receiving a discreet injection at a clinic every two months does not have a pill bottle at home that could reveal their HIV status to a roommate or family member, which remains a meaningful concern for many people living with HIV.²⁴ The trade-off is that the injections are currently approved only for people who are already virally suppressed, and missing an injection appointment can create a period of subtherapeutic drug levels that risks resistance.

Preventing Mother-to-Child Transmission

HAART has been transformative for pregnant women living with HIV. Without treatment, the virus can pass to a baby during pregnancy, labor, or breastfeeding. With effective antiretroviral therapy, that risk drops dramatically. In one study, up to 90% of children born to mothers who received HAART were confirmed HIV-negative.²⁵

Timing matters considerably. Women who started HAART at least 13 weeks before delivery had much lower transmission rates than those who started four weeks or fewer before giving birth, where the odds of transmission were roughly five times higher.²⁶ Each additional week of treatment before delivery reduced the odds of transmission by about 14%. This is a strong argument for early prenatal HIV testing and prompt treatment initiation rather than waiting until later in pregnancy.²⁷

Immune Reconstitution Inflammatory Syndrome

Starting HAART is not always a smooth process, especially for people who begin treatment with very low CD4 counts. As the immune system revives, it can mount an aggressive inflammatory response against infections that were already present but kept in check (or hidden) by the weakened immune state. This reaction is called immune reconstitution inflammatory syndrome, or IRIS. It can target bacteria, fungi, viruses, or even tumor cells, producing a wide range of symptoms depending on what the immune system suddenly “sees.” The most common triggers are mycobacterial infections, fungal infections, and herpes viruses.²⁸

The risk of IRIS is strongly tied to how depleted the immune system is at the time treatment starts. People with fewer than 50 CD4 cells per microliter face the highest risk.²⁹ People with undiagnosed opportunistic infections are also at risk for “unmasking” IRIS, where a hidden infection flares up once the immune system wakes up.³⁰ This is another reason early treatment, before severe immune damage, is preferred whenever possible. IRIS is usually self-limiting or manageable with anti-inflammatory drugs, but in rare cases it can be life-threatening.

Reaching the Brain

HIV can establish itself in the central nervous system, and not all antiretroviral drugs cross the blood-brain barrier equally well. Researchers have developed a scoring system (the CNS penetration effectiveness score, or CPE) to rank how well different regimens reach the brain. The theory was that regimens with higher penetration would better control the virus in the brain and protect against HIV-associated cognitive problems.

The reality is more complicated. A review of 23 studies found that higher CPE scores were not as strongly linked to better cognitive outcomes as initially hoped, though there were modest associations with improved global cognitive functioning and some benefit for attention and memory.³¹ Earlier data had been more encouraging, suggesting that high-penetration regimens lowered viral levels in spinal fluid and improved neurocognitive performance.³² The disconnect suggests that HIV-related cognitive decline involves more than just viral replication in the brain. Chronic inflammation, the drugs themselves, and the aging process all likely play a role, and choosing a regimen based solely on brain penetration scores does not seem to be the solution.

Global Rollout and the Treat All Approach

The knowledge that treatment prevents transmission helped drive the WHO’s “Treat All” recommendation, which advises starting antiretroviral therapy for everyone diagnosed with HIV, regardless of CD4 count or clinical stage. In Namibia, after implementing this approach, the odds of rapid treatment initiation within seven days of diagnosis increased more than fivefold. Among people already established on treatment, the odds of achieving viral suppression more than tripled.³³

But the benefits of Treat All have not come without complications. In the same Namibian evaluation, loss to follow-up nearly doubled after the policy was introduced, likely because rapid initiation did not always include adequate counseling or support. The first randomized trial to test whether immediate treatment at the population level could reduce new infections struggled to show a clear benefit, largely because getting people consistently linked to and retained in care proved difficult in practice.³⁴ The science of treatment as prevention is robust; the challenge is making health systems work well enough to deliver on it.

Drug-Food Interactions and Everyday Practicalities

One underappreciated aspect of HAART is how much food timing matters. A systematic review found clinically meaningful food interactions for more than half of antiretroviral agents.³⁵ Some drugs should be taken with a meal: tenofovir disoproxil, rilpivirine, dolutegravir, elvitegravir, darunavir, and lopinavir among them. Others work best on an empty stomach, including efavirenz and zidovudine. Getting this wrong can reduce how much drug gets absorbed or increase side effects. For people on complex regimens that combine drugs with different food requirements, the practical choreography of when to eat and when to take pills adds a real burden on top of the daily commitment to lifelong therapy.

Managing Co-Infections

Many people living with HIV also carry hepatitis B, hepatitis C, or tuberculosis, and these co-infections complicate treatment in ways that go beyond simply adding more pills.³⁶ The drugs used to treat tuberculosis, for instance, are notorious for interacting with antiretrovirals. Rifampicin, a cornerstone of TB treatment, powerfully accelerates the breakdown of many HIV drugs in the liver, reducing their effectiveness. The treatments for cryptococcal meningitis and pneumocystis pneumonia also present interaction risks that require careful regimen selection.³⁷ Hepatitis B adds a unique wrinkle: some antiretrovirals (particularly tenofovir-based drugs) are active against both HIV and hepatitis B, so stopping or switching those drugs can trigger a dangerous hepatitis B flare. Managing these overlapping infections requires coordination between treatment plans in a way that few other chronic diseases demand.

Quality of Life as a Lifelong Patient

The shift from a fatal to a chronic disease has created a new set of concerns centered on quality of life over decades rather than survival over months. Researchers have identified dimensions of well-being specific to people on long-term HAART that do not map neatly onto generic health questionnaires: fears of infecting others, anxiety about the future, satisfaction with care, work disruption, and the psychological weight of knowing therapy is permanent.³⁸ Some patients report depression linked to the indefinite nature of treatment and its side effects.³⁹ Stigma remains a powerful factor: in many communities, the fear of being identified as HIV-positive still shapes whether people start treatment, stay on it, or hide their medication from family. The science of HAART is one of modern medicine’s great achievements, but the lived experience of taking it every day, for the rest of your life, remains a deeply human challenge that pharmacology alone cannot fully address.

1
Nature. A mechanistic theory to explain the efficacy of antiretroviral therapy ↩︎
2
European Journal of Public Health. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? ↩︎
3
PubMed Central. Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children during the HAART Era ↩︎
4
The Lancet. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease ↩︎
5
PubMed Central. Dolutegravir based therapy showed CD4(+) T cell count recovery and viral load suppression among ART naïve people living with HIV AIDS: a pilot evaluation ↩︎
6
PLOS ONE. Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS ↩︎
7
The Lancet. Risk of sexual transmission of HIV in serodifferent couples using suppressive antiretroviral therapy (PARTNER2) ↩︎
8
PubMed Central. Global response to HIV: treatment as prevention, or treatment for treatment? ↩︎
9
PubMed Central. Achieving a cure for HIV infection: do we have reasons to be optimistic? ↩︎
10
PubMed Central. Challenges and strategies for the eradication of the HIV reservoir ↩︎
11
PubMed Central. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure ↩︎
12
PubMed Central. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance ↩︎
13
PubMed Central. The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes ↩︎
14
PubMed. Adherence-resistance relationships to combination HIV antiretroviral therapy ↩︎
15
PubMed Central. Experience of a Nationwide implementation of single-tablet second-generation integrase inhibitors-based treatment in Mexico ↩︎
16
PubMed Central. A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients: Renal and bone safety versus antiviral efficacy ↩︎
17
PubMed. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment ↩︎
18
Open Forum Infectious Diseases. 1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial ↩︎
19
PubMed Central. Weight Gain and Integrase Inhibitors ↩︎
20
PubMed Central. The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions ↩︎
21
Scientific Reports. Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study ↩︎
22
Heart. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania ↩︎
23
PubMed. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression ↩︎
24
PubMed Central. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV ↩︎
25
PubMed Central. Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women ↩︎
26
PubMed Central. Optimal Time on HAART for Prevention of Mother-to-Child Transmission of HIV ↩︎
27
PubMed Central. Maternal Interventions to Prevent Mother-To-Child Transmission of HIV: Moving Beyond Antiretroviral Therapy ↩︎
28
PubMed. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management ↩︎
29
PubMed Central. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis ↩︎
30
PubMed. Therapeutics targeting inflammation in the immune reconstitution inflammatory syndrome ↩︎
31
PubMed Central. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score ↩︎
32
PubMed Central. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder ↩︎
33
PLoS ONE. Effects of the implementation of the HIV Treat All guidelines on key ART treatment outcomes in Namibia ↩︎
34
PubMed Central. Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All ↩︎
35
PubMed Central. Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses ↩︎
36
PubMed. Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection ↩︎
37
PubMed. Managing Drug Interactions between Antiretrovirals and Opportunistic Infections in People with HIV ↩︎
38
JAIDS Journal of Acquired Immune Deficiency Syndromes. The Development of PROQOL-HIV ↩︎
39
Journal of Public Health and Epidemiology. Quality of life of HIV patients on highly active antiretroviral therapy: A scoping review ↩︎